Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$6.99 USD

6.99
415,276

+0.25 (3.71%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $6.99 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Instruments

Zacks News

Cooper Companies' (COO) Buyout to Boost Women's Healthcare

Cooper Companies' (COO) agrees to acquire Generate Life Sciences. It will be an important addition to the former's present offerings, while improving women's healthcare.

Surmodics (SRDX) Stock Loses 2.2% Despite Q4 Earnings Beat

Surmodics' (SRDX) fiscal fourth-quarter results reflect benefits from segmental strength.

Shockwave Medical (SWAV) Gains 0.6% Post Q3 Earnings Beat

Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and expansion in gross margin.

Inari Medical (NARI) Q3 Earnings and Revenues Beat Estimates

Inari Medical's (NARI) third-quarter results benefit from new product launches and continued U.S. commercial expansion.

Cardinal Health (CAH) Q1 Earnings Lag, Revenues Top Estimates

Although Cardinal Health (CAH) witnessed gross margin contraction in its fiscal first-quarter results, rise in revenues in both its segments is encouraging.

AMN Healthcare (AMN) Loses 13.1% Despite Q3 Earnings Beat

AMN Healthcare's (AMN) robust Q3 results demonstrate its segmental strength.

Glaukos (GKOS) Gains 3.6% Despite Reporting a Loss in Q3

Despite reporting third-quarter loss, Glaukos' (GKOS) results reflect a significant rise in revenues.

LHC Group (LHCG) Q3 Earnings Match Estimates, Down Y/Y

LHC Group's (LHCG) third-quarter results benefit from organic growth in both home health and hospice admissions.

Inogen (INGN) Earnings and Revenues Surpass Estimates in Q3

Inogen's (INGN) third-quarter results benefit from higher revenues across its segments.

AmerisourceBergen (ABC) Q4 Earnings & Revenues Top Estimates

AmerisourceBergen's (ABC) fiscal fourth-quarter results benefit from segmental growth.

DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Beat Estimates

DENTSPLY SIRONA's (XRAY) third-quarter results benefit from strong segmental performance.

Change Healthcare (CHNG) Q2 Earnings Beat, Revenues Miss

Change Healthcare's (CHNG) fiscal second-quarter results benefit from solid performance across Software and Analytics and Network Solutions segments.

Fresenius Medical (FMS) Q3 Earnings Beat Estimates, Down Y/Y

Fresenius Medical's (FMS) third-quarter earnings benefit from strong performance across the regions, Asia Pacific and Latin America.

PerkinElmer (PKI) Q3 Earnings and Revenues Surpass Estimates

PerkinElmer's (PKI) third-quarter results benefit from strong segmental performance.

Catalent (CTLT) Q1 Earnings Top Estimates, FY22 View Up

Catalent's (CTLT) robust performance across most of its segments drives its first-quarter fiscal 2022 top line.

McKesson (MCK) Earnings and Revenues Beat Estimates in Q2

McKesson's (MCK) fiscal second-quarter 2022 results benefit from substantial growth in the Medical-Surgical Solutions business.

NextGen Healthcare (NXGN) Gains 9.7% Since Q2 Earnings Beat

NextGen Healthcare's (NXGN) fiscal second-quarter earnings reflect strong segmental performance.

OPKO Health's (OPK) Q3 Earnings, Revenues Top Estimates

OPKO Health's (OPK) third-quarter results benefit from strength in its Pharmaceuticals segment, backed by robust RAYALDEE sales.

Integer Holdings (ITGR) Beats on Q3 Earnings, Ups 2021 EPS View

Integer Holdings' (ITGR) third-quarter results reflect robust segmental performances along with strength in the majority of the product lines.

Merit Medical's (MMSI) Q3 Earnings, Revenues Top Estimates

Merit Medical (MMSI), in the third quarter, benefits from revenue growth in its Cardiovascular segment, and from the majority of the product categories within its Cardiovascular unit.

Cerner (CERN) Q3 Earnings and Revenues Surpass Estimates

Cerner's (CERN) third-quarter results benefit from gains across four of its business units.

DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates

DexCom's (DXCM) third-quarter results benefit from domestic and international revenue growth and solid new customer additions.

Stryker (SYK) Earnings and Revenues Miss Estimates in Q3

Despite pandemic-led disruptions, Stryker's (SYK) third-quarter earnings reflect strong performance across Orthopaedics, MedSurg and Neurotechnology and Spine segments.

DaVita (DVA) Beats on Q3 Earnings, Narrows 2021 EPS View

DaVita's (DVA) strength in dialysis patient service revenues drives its Q3 top line.

AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates

AngioDynamics (ANGO) registers strong revenue growth across the majority of its GBUs as well as in domestic revenues in fiscal 2022 Q1.